Medtronic PLC $MDT Position Decreased by TD Waterhouse Canada Inc.

Key Points

• TD Waterhouse Canada reduced its Medtronic position by 4.6%, selling 16,687 shares and retaining 343,172 shares valued at approximately $28.56 million. Institutional investors collectively own 82.06% of the company.
• Medtronic’s latest quarterly results exceeded expectations, with adjusted EPS of $1.45 and revenue of $9.76 billion; revenue increased 13.7% year over year. The company also pays a quarterly dividend of $0.72, equivalent to a 3.0% annualized yield.
• Company insiders sold 61,903 shares worth roughly $5.89 million over the past three months, including CEO Geoffrey Martha’s $4.75 million sale under a Rule 10b5-1 plan. Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $102.88.

TD Waterhouse Canada Inc. lowered its position in Medtronic PLC (NYSE:MDT - Free Report) by 4.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 343,172 shares of the medical technology company's stock after selling 16,687 shares during the period. TD Waterhouse Canada Inc.'s holdings in Medtronic were worth $28,560,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of MDT. Monetary Solutions Ltd acquired a new stake in Medtronic in the fourth quarter worth about $27,000. Activest Wealth Management grew its stake in shares of Medtronic by 470.9% during the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock worth $27,000 after acquiring an additional 259 shares during the last quarter. IAG Wealth Partners LLC acquired a new position in shares of Medtronic during the second quarter valued at about $30,000. Pin Oak Investment Advisors Inc. acquired a new position in shares of Medtronic during the second quarter valued at about $32,000. Finally, Global Assets Advisory LLC acquired a new position in shares of Medtronic during the first quarter valued at about $36,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Geoffrey Martha sold 50,000 shares of the company's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares of the company's stock, valued at approximately $26,397,270. The trade was a 15.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 61,903 shares of company stock worth $5,889,203. Corporate insiders own 0.27% of the company's stock.

Medtronic Price Performance

NYSE:MDT opened at $94.79 on Friday. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $121.25 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.55. The stock's 50-day moving average price is $91.03 and its 200-day moving average price is $85.01.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 25th. Medtronic's payout ratio is presently 70.94%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MDT. TD Cowen reissued a "buy" rating and set a $110.00 price objective on shares of Medtronic in a report on Wednesday, September 30th. Wells Fargo & Company raised their target price on Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 2nd. Royal Bank Of Canada restated an "outperform" rating and issued a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Finally, Weiss Ratings upgraded Medtronic from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, September 4th. Seventeen investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $102.88.

About Medtronic

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.